Views & Analysis Integrating patient insights and real-world data: the future... Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Views & Analysis Outcomes-based medicine demands real-world evidence RWE must become a fundamental accompaniment to traditional RCT data.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends